HK1218232A1 - 使用工程化鋅指蛋白核酸酶靶向斷裂t細胞受體基因 - Google Patents

使用工程化鋅指蛋白核酸酶靶向斷裂t細胞受體基因 Download PDF

Info

Publication number
HK1218232A1
HK1218232A1 HK16106201.4A HK16106201A HK1218232A1 HK 1218232 A1 HK1218232 A1 HK 1218232A1 HK 16106201 A HK16106201 A HK 16106201A HK 1218232 A1 HK1218232 A1 HK 1218232A1
Authority
HK
Hong Kong
Prior art keywords
cells
tcr
gene
cell
sequence
Prior art date
Application number
HK16106201.4A
Other languages
English (en)
Chinese (zh)
Inventor
‧格雷戈里
P‧D‧格雷戈里
‧霍爾姆斯
M‧C‧霍尔姆斯
‧帕斯喬恩
D‧帕斯乔恩
張雷
张雷
‧伯尼尼
M‧C‧伯尼尼
‧格諾韋塞
P‧格诺韦塞
‧馬格納尼
Z‧马格纳尼
‧馬斯塔格里奧
S‧马斯塔格里奥
‧那爾蒂尼
L‧那尔蒂尼
Original Assignee
桑格摩生物科学股份有限公司
圣拉斐尔医院有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 桑格摩生物科学股份有限公司, 圣拉斐尔医院有限公司 filed Critical 桑格摩生物科学股份有限公司
Publication of HK1218232A1 publication Critical patent/HK1218232A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK16106201.4A 2013-03-21 2014-03-20 使用工程化鋅指蛋白核酸酶靶向斷裂t細胞受體基因 HK1218232A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361804076P 2013-03-21 2013-03-21
US61/804,076 2013-03-21
PCT/US2014/031360 WO2014153470A2 (en) 2013-03-21 2014-03-20 Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases

Publications (1)

Publication Number Publication Date
HK1218232A1 true HK1218232A1 (zh) 2017-02-10

Family

ID=51581806

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106201.4A HK1218232A1 (zh) 2013-03-21 2014-03-20 使用工程化鋅指蛋白核酸酶靶向斷裂t細胞受體基因

Country Status (9)

Country Link
US (2) US9937207B2 (enExample)
EP (1) EP2975942B1 (enExample)
JP (1) JP6346266B2 (enExample)
CN (1) CN105208866B (enExample)
AU (1) AU2014235968B2 (enExample)
CA (1) CA2906970C (enExample)
HK (1) HK1218232A1 (enExample)
IL (1) IL241583B (enExample)
WO (1) WO2014153470A2 (enExample)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
US9528124B2 (en) 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
RU2645475C2 (ru) 2012-04-25 2018-02-21 Регенерон Фармасьютикалз, Инк. Опосредованное нуклеазой нацеливание с большими нацеливающими векторами
JP2016522679A (ja) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
DK2986729T3 (en) 2013-04-16 2018-10-29 Regeneron Pharma TARGETED MODIFICATION OF ROOT THROUGH
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
GB201315321D0 (en) * 2013-08-28 2013-10-09 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction Buffer
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
KR102595473B1 (ko) * 2014-04-18 2023-10-30 에디타스 메디신, 인코포레이티드 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분
RU2704283C9 (ru) * 2014-06-06 2020-02-07 Регенерон Фармасьютикалз, Инк. Способы и композиции для модификации целевого локуса
PT3161128T (pt) 2014-06-26 2018-11-21 Regeneron Pharma Métodos e composições para modificações genéticas alvejadas e métodos de utilização
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CA2959070C (en) 2014-08-27 2020-11-10 Caribou Biosciences, Inc. Methods for increasing cas9-mediated engineering efficiency
KR20170075013A (ko) 2014-10-31 2017-06-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cart 세포에서 유전자 발현의 변경 및 그의 용도
EP3215623A4 (en) 2014-11-06 2018-09-26 President and Fellows of Harvard College Cells lacking b2m surface expression and methods for allogeneic administration of such cells
CA2968440A1 (en) 2014-11-21 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
BR112017013104A2 (en) 2014-12-19 2018-05-15 Regeneron Pharmaceuticals, Inc. methods for modifying a target genomic locus in a cell, for enhancing homologous recombination at a target genomic locus in a cell, and for producing an f0 generation from a nonhuman animal.
AU2016243583B2 (en) * 2015-03-27 2022-03-10 President And Fellows Of Harvard College Modified T cells and methods of making and using the same
WO2016161446A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
CA2988854A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
KR102197507B1 (ko) 2015-07-13 2020-12-31 피벗 바이오, 인크. 식물 형질 개선을 위한 방법 및 조성물
JP7602862B2 (ja) * 2015-07-25 2024-12-19 ハビブ・フロスト がんおよび他の病的状態における治療または治癒を提供する、システム、デバイスおよび方法
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
GB2557123B (en) 2015-07-31 2021-11-03 Univ Minnesota Modified cells and methods of therapy
EP4108255A1 (en) 2015-10-05 2022-12-28 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
WO2017062412A1 (en) 2015-10-05 2017-04-13 Massachusetts Institute Of Technology Nitrogen fixation using refactored nif clusters
ES2883116T3 (es) 2015-10-05 2021-12-07 Prec Biosciences Inc Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
CN116059316A (zh) * 2015-10-23 2023-05-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
GB201521101D0 (en) 2015-11-30 2016-01-13 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction buffer
AU2016374253B2 (en) 2015-12-18 2021-10-21 Sangamo Therapeutics, Inc. Targeted disruption of the MHC cell receptor
ES2983043T3 (es) 2015-12-18 2024-10-21 Sangamo Therapeutics Inc Alteración dirigida del receptor de células T
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
ES3039670T3 (en) 2016-04-15 2025-10-23 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
IL300783B2 (en) 2016-08-24 2026-03-01 Sangamo Therapeutics Inc Engineered nucleases with target-specific zinc fingers
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB201616238D0 (en) * 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
CA3105873A1 (en) * 2016-09-30 2018-04-05 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
EP3519433A1 (en) 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-specific binding molecules
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
CN111344396A (zh) * 2016-10-27 2020-06-26 因提玛生物科学公司 制备遗传修饰细胞的病毒方法
CA3039420A1 (en) 2016-11-07 2018-05-11 Genovie Ab A two-part device for t-cell receptor synthesis and stable genomic integration to tcr-presenting cells
JP6858266B2 (ja) * 2016-11-07 2021-04-14 ジェノヴィー エービーＧｅｎｏｖｉｅ Ａｂ Ｔ細胞レセプター、ｔ細胞抗原及びそれらの機能的相互作用の同定及び特徴決定のための遺伝子操作された多成分システム
CA3038917A1 (en) 2016-11-07 2018-05-11 Genovie Ab An engineered multi-component system for identification and characterisation of t-cell receptors and t-cell antigens
JP7582779B2 (ja) * 2016-11-07 2024-11-13 ジェノヴィー エービー Ｔ細胞レセプターの同族抗原との相互作用の発見及び特徴決定のための遺伝子操作された二部構成細胞デバイス
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
UA129256C2 (uk) 2017-01-12 2025-03-05 Півот Байо, Інк. Спосіб ідентифікації штаму мікроорганізму, який продукує азот, небобова рослина, колонізована таким штамом, спосіб збільшення фіксації азоту у небобових рослин та композиція для збільшення фіксації азоту у небобових рослин
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
AU2018258045B2 (en) 2017-04-26 2024-02-29 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
SG11201912179SA (en) 2017-06-15 2020-01-30 Univ California Targeted non-viral dna insertions
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
CA3067914A1 (en) 2017-06-30 2019-01-03 Cellectis Cellular immunotherapy for repetitive administration
JP2020529834A (ja) 2017-06-30 2020-10-15 プレシジョン バイオサイエンシズ，インク． Ｔ細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変ｔ細胞
CA3068634A1 (en) 2017-06-30 2019-01-03 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
CA3071683A1 (en) 2017-08-08 2019-02-14 Sangamo Therapeutics, Inc. Chimeric antigen receptor mediated cell targeting
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
BR112020005938A2 (pt) * 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
CN111479830A (zh) * 2017-10-10 2020-07-31 国立大学法人广岛大学 使用铂talen的t细胞受体的完全取代技术
EP3702454A4 (en) * 2017-10-10 2021-08-04 Hiroshima University METHOD FOR GENERATING ANTIGEN-SPECIFIC REGULATORY T-CELLS (TREG) WITH EFFECTOR T-CELL (TEFF) ANTIGEN RECEPTORS
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
JP7420712B2 (ja) 2017-10-25 2024-01-23 ピボット バイオ， インコーポレイテッド 窒素を固定する操作された微生物を改良するための方法および組成物
US12151988B2 (en) 2017-10-25 2024-11-26 Pivot Bio, Inc. Gene targets for nitrogen fixation targeting for improving plant traits
WO2019084552A1 (en) 2017-10-27 2019-05-02 The Regents Of The University Of California TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS
RU2020116585A (ru) * 2017-10-30 2021-12-01 Пэкт Фарма, Инк. Редактирование гена первичных клеток
BR112020008568A2 (pt) * 2017-11-09 2020-10-06 Sangamo Therapeutics, Inc. modificação genética de gene de proteína contendo sh2 indutível por citoquina (cish)
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
AU2019206443A1 (en) * 2018-01-10 2020-07-23 Cmc Icos Biologics, Inc. Bidirectional CHEFl vectors
AU2019216982B2 (en) * 2018-02-11 2024-07-04 Memorial Sloan-Kettering Cancer Center Non-HLA restricted T cell receptors and uses thereof
SG11202007697VA (en) 2018-02-15 2020-09-29 Memorial Sloan Kettering Cancer Center Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
SG11202009761YA (en) 2018-04-02 2020-10-29 Pact Pharma Inc Peptide-mhc compacts
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
AU2019247199A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
EP3775238A1 (en) * 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
JP7304888B2 (ja) 2018-04-12 2023-07-07 プレシジョン バイオサイエンシズ，インク． ヒトｔ細胞受容体アルファ定常領域遺伝子に特異性を有する最適化された操作されたヌクレアーゼ
US20200208177A1 (en) * 2018-04-18 2020-07-02 Ligandal, Inc. Methods and compositions for genome editing
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3813511A4 (en) 2018-06-27 2022-08-03 Pivot Bio, Inc. GUIDED MICROBIAL REMODELING, PLATFORM FOR RATIONAL IMPROVEMENT OF MICROBIAL SPECIES FOR AGRICULTURE
EP3814302A4 (en) 2018-06-27 2022-06-29 Pivot Bio, Inc. Agricultural compositions comprising remodeled nitrogen fixing microbes
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
US12391624B2 (en) 2018-07-11 2025-08-19 Pivot Bio, Inc. Temporally and spatially targeted dynamic nitrogen delivery by remodeled microbes
JP7250031B2 (ja) * 2018-09-25 2023-03-31 公益財団法人微生物化学研究会 新規ウイルスベクターおよびその製造方法と使用方法
MX2021004214A (es) * 2018-10-16 2021-07-15 Intellia Therapeutics Inc Composiciones y metodos de inmunoterapia.
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
GB201817821D0 (en) * 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
WO2020128618A2 (en) 2018-12-18 2020-06-25 Braskem S.A. Co-production pathway for 3-hp and acetyl-coa derivatives from malonate semialdehyde
US20220017911A1 (en) 2018-12-21 2022-01-20 Pivot Bio, Inc. Methods, compositions, and media for improving plant traits
EP3880807A2 (en) 2018-12-28 2021-09-22 Braskem S.A. Modulation of carbon flux through the meg and c3 pathways for the improved production of monoethylene glycol and c3 compounds
US12421519B2 (en) 2019-01-07 2025-09-23 Pivot Bio, Inc. Plant colonization assays using natural microbial barcodes
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021009640A (es) 2019-02-12 2021-10-13 Pact Pharma Inc Composiciones y metodos para la identificacion de celulas t especificas de antigenos.
CN113748211A (zh) 2019-03-01 2021-12-03 布拉斯科公司 用于4-羟甲基糠醛及其衍生物的体内合成的方法
EP3942043A2 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020190363A1 (en) 2019-03-19 2020-09-24 Massachusetts Institute Of Technology Control of nitrogen fixation in rhizobia that associate with cereals
WO2020206248A1 (en) 2019-04-03 2020-10-08 Precision Biosciences, Inc. Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
JP7715636B2 (ja) 2019-04-04 2025-07-30 ブラスケム エス．エー． 第二世代の糖から化学物質を生成するためのキシロースおよびグルコースの同時消費のための代謝工学
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN114364788A (zh) 2019-04-24 2022-04-15 皮沃特生物股份有限公司 用于靶向固氮以改良植物性状的基因靶标
CN114008221A (zh) 2019-04-25 2022-02-01 皮沃特生物股份有限公司 用于分离和表征由化学诱变产生的泌铵突变体库的高通量方法
AU2020267057A1 (en) 2019-04-30 2021-11-18 Crispr Therapeutics Ag Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
JP2022533713A (ja) 2019-05-21 2022-07-25 サンガモ セラピューティクス， インコーポレイテッド 調節性ｔ細胞における制御された導入遺伝子発現
WO2021016608A1 (en) 2019-07-25 2021-01-28 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
AU2020333851A1 (en) 2019-08-20 2022-03-31 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
CN110484523A (zh) * 2019-09-06 2019-11-22 上海斯丹赛生物技术有限公司 一种锌指核酸酶及其应用
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US20240398862A1 (en) * 2019-10-15 2024-12-05 The Regents Of The University Of California Gene targets for manipulating t cell behavior
WO2021087305A1 (en) 2019-10-30 2021-05-06 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
WO2021221690A1 (en) 2020-05-01 2021-11-04 Pivot Bio, Inc. Modified bacterial strains for improved fixation of nitrogen
AU2020445067A1 (en) 2020-05-01 2022-12-01 Pivot Bio, Inc. Measurement of nitrogen fixation and incorporation
CA3172322A1 (en) 2020-05-01 2021-11-04 Karsten TEMME Modified bacterial strains for improved fixation of nitrogen
WO2021222643A1 (en) 2020-05-01 2021-11-04 Pivot Bio, Inc. Stable liquid formulations for nitrogen-fixing microorganisms
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
EP4149245A2 (en) 2020-05-13 2023-03-22 Pivot Bio, Inc. De-repression of nitrogen fixation in gram-positive microorganisms
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
US20260028412A1 (en) 2020-08-10 2026-01-29 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
EP4284823A1 (en) 2021-01-28 2023-12-06 Precision BioSciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
AU2022301301A1 (en) 2021-07-02 2023-12-14 Pivot Bio, Inc. Genetically-engineered bacterial strains for improved fixation of nitrogen
IL311570A (en) 2021-10-14 2024-05-01 Arsenal Biosciences Inc Immune cells with common expression chain and logic gate systems
JP2024539291A (ja) * 2021-10-25 2024-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経膠芽腫を治療するための方法および組成物
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method
WO2023201133A1 (en) 2022-04-14 2023-10-19 Board Of Regents Of The University Of Nebraska Cell therapy for alzheimer's disease
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024137259A1 (en) 2022-12-23 2024-06-27 Pivot Bio, Inc. Combination of various nitrogen fixing bacteria with various biological products to achieve synergistic effects
WO2024148167A1 (en) 2023-01-05 2024-07-11 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
WO2025155521A1 (en) 2024-01-18 2025-07-24 Pivot Bio, Inc. Host cells for enhanced plant growth
WO2025155518A1 (en) 2024-01-18 2025-07-24 Pivot Bio, Inc. Host cells for enhanced plant growth
WO2026025092A1 (en) 2024-07-26 2026-01-29 Juno Therapeutics, Inc. Synthetic promoters for t cell expression

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
EP0770129B1 (en) 1994-01-18 2005-11-23 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
CA2196419C (en) 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
HK1049515B (en) 1999-12-06 2006-01-13 Sangamo Biosciences Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
DE60143192D1 (de) 2000-02-08 2010-11-18 Sangamo Biosciences Inc Zellen zur entdeckung von medikamenten
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
US20030044787A1 (en) 2000-05-16 2003-03-06 Joung J. Keith Methods and compositions for interaction trap assays
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
AU2003251286B2 (en) 2002-01-23 2007-08-16 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
JP2006502748A (ja) 2002-09-05 2006-01-26 カリフォルニア インスティテュート オブ テクノロジー 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法
DK1616012T3 (da) 2003-04-24 2008-04-21 San Raffaele Centro Fond Lentivirale vektorer bærende syntetiske bidirektionelle promotorer og anvendelser deraf
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JP4773434B2 (ja) 2004-05-19 2011-09-14 イムノコア リミテッド 高親和性ｎｙ−ｅｓｏｔ細胞受容体
EP2292274A1 (en) 2004-09-16 2011-03-09 Sangamo BioSciences, Inc. Compositions and methods for protein production
WO2007014275A2 (en) 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
EP1941028A2 (en) 2005-08-08 2008-07-09 Fondazione Centro San Raffaele Del Monte Tabor Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes.
AU2007248019B2 (en) 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
WO2007136685A2 (en) 2006-05-19 2007-11-29 Sangamo Biosciences, Inc. Methods and compositions for inactivation of dihydrofolate reductase
JP5266210B2 (ja) 2006-05-25 2013-08-21 サンガモ バイオサイエンシズ インコーポレイテッド 改変開裂ハーフドメイン
ES2465996T3 (es) 2006-05-25 2014-06-09 Sangamo Biosciences, Inc. Métodos y composiciones para la inactivación genética
CA2684378C (en) 2007-04-26 2016-11-29 Sangamo Biosciences, Inc. Targeted integration into the ppp1r12c locus
EP2172547B1 (en) * 2007-06-11 2016-01-06 Takara Bio Inc. Method for expression of specific gene
AU2008317354B2 (en) 2007-10-25 2014-04-10 Ospedale San Raffaele S.R.L. Methods and compositions for targeted integration
JP2011518555A (ja) 2008-04-14 2011-06-30 サンガモ バイオサイエンシーズ， インコーポレイテッド 標的組込みのための線形ドナーコンストラクト
EP2294191B1 (en) 2008-06-10 2016-09-28 Sangamo BioSciences, Inc. Methods and compositions for generation of bax- and bak-deficient cell lines
AU2009283194B2 (en) 2008-08-22 2014-10-16 Sangamo Therapeutics, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
AU2009322964B2 (en) 2008-12-04 2014-10-09 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2010107493A2 (en) * 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
CA2767377A1 (en) * 2009-07-24 2011-01-27 Sigma-Aldrich Co. Llc Method for genome editing
EP3156504B1 (en) * 2009-08-11 2018-10-31 Sangamo Therapeutics, Inc. Organisms homozygous for targeted modification
US8956828B2 (en) * 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011097036A1 (en) 2010-02-08 2011-08-11 Sangamo Biosciences, Inc. Engineered cleavage half-domains
JP2013518602A (ja) 2010-02-09 2013-05-23 サンガモ バイオサイエンシーズ， インコーポレイテッド 部分的に一本鎖のドナー分子による標的化ゲノム改変
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
EP3156062A1 (en) * 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
CA3157027A1 (en) * 2010-07-21 2012-01-26 Sangamo Therapeutics, Inc. Methods and compositions for modification of a t-cell receptor gene
JP5996630B2 (ja) * 2011-04-05 2016-09-21 セレクティスＣｅｌｌｅｃｔｉｓ コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用
US9400576B2 (en) 2011-07-19 2016-07-26 Apple Inc. Touch sensor arrangements for organic light-emitting diode displays
US9150847B2 (en) 2011-09-21 2015-10-06 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
US8895264B2 (en) 2011-10-27 2014-11-25 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
JP6559063B2 (ja) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物

Also Published As

Publication number Publication date
US20180214485A1 (en) 2018-08-02
EP2975942A4 (en) 2016-11-09
JP2016515822A (ja) 2016-06-02
WO2014153470A3 (en) 2014-12-04
CA2906970C (en) 2021-05-18
US20140301990A1 (en) 2014-10-09
JP6346266B2 (ja) 2018-06-20
US10918668B2 (en) 2021-02-16
CN105208866A (zh) 2015-12-30
CN105208866B (zh) 2018-11-23
IL241583B (en) 2021-05-31
AU2014235968A1 (en) 2015-10-01
WO2014153470A2 (en) 2014-09-25
US9937207B2 (en) 2018-04-10
CA2906970A1 (en) 2014-09-25
EP2975942A2 (en) 2016-01-27
EP2975942B1 (en) 2018-08-08
AU2014235968B2 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
US10918668B2 (en) Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US20230346844A1 (en) Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
JP7348160B2 (ja) ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法及び組成物
US9757420B2 (en) Gene editing for HIV gene therapy
EP3057432B1 (en) Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
US20140140969A1 (en) Methods and compositions for muscular dystrophies
KR20200035127A (ko) 키메라 항원 수용체 매개된 세포 표적화
EP2764102A1 (en) Methods and compositions for regulating hiv infection
JP2016539627A (ja) ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法および組成物
EP2622090A1 (en) Methods and compositions for inhibiting viral entry into cells
JP2022105621A (ja) 造血幹細胞および前駆細胞におけるｓｃｉｄ関連遺伝子の遺伝子修正
HK1260200A1 (en) Targeted disruption of the mhc cell receptor